Current endocrine and targeted treatment of metastatic ER+ breast cancer

Current endocrine and targeted treatment of metastatic ER+ breast cancer. Antiestrogen therapy including selective estrogen receptor modulators (tamoxifen), aromatase inhibitors (anastrazole, letrozole, exemestane), and selective estrogen receptor degraders (fulvestrant) continues to be the treatment backbone of hormone receptor-positive breast cancer since tamoxifen FDA approval in 1977. Improvement in the understanding of the molecular biology of estrogen-positive breast cancer led to the development of effective targeted therapies such as CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) and inhibitors of PI3K/Akt/mTOR signaling pathway (alpelisib, capivasertib), as well as improvement in the delivery and potency of traditional endocrine therapy including oral selective estrogen receptor degraders (elacestrant). * Anticipated regulatory approval during the fourth quarter of 2023. Abbreviations: AKT, AKT Serine/Threonine Kinase 1; CDK, cyclin-dependent kinase; ER, estrogen receptor; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinases; SERD, selective estrogen receptor degraders; SERM, selective estrogen receptor modulator
Current endocrine and targeted treatment of metastatic ER+ breast cancer

Publication

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches (2023) Farah Raheem, et al. Int J Mol Sci. 2023 Nov;24(22). Figure: F1.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CDK4/6 CDK4 ncbigene_symbol CDK4 1019
Homo sapiens Primates CDK4/6 CDK6 ncbigene_symbol CDK6 1021
Homo sapiens Primates AKT AKT ncbigene_synonym AKT1 207
Homo sapiens Primates AKT AKT famplex_relations AKT2 208
Homo sapiens Primates AKT AKT famplex_relations AKT3 10000
Homo sapiens Primates mTOR MTOR ncbigene_symbol MTOR 2475

Chemical mentions

Word Match MeSH Name ChEBI
Anastrozole anastrozole 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile) chebi:2704
Inhibitor inhibitor inhibitor chebi:35222
Letrozole letrozole 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile chebi:6413
inhibitors inhibitors inhibitor chebi:35222
Exemestane exemestane 6-methylideneandrosta-1,4-diene-3,17-dione chebi:4953
Fulvestrant fulvestrant 7alpha-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17beta-diol chebi:31638
Palbociclib palbociclib 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one chebi:85993
Elacestrant elacestrant (6R)-6-[2-(ethyl{4-[2-(ethylamino)ethyl]benzyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol chebi:229213
Tamoxifen tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine chebi:41774
inhibitor inhibitor inhibitor chebi:35222
inhibitor inhibitor inhibitor chebi:35222
Everolimus everolimus (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone chebi:68478

Disease mentions

Word Match MeSH Name DOID